跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Recombinant Human Plasminogen Activator
首页
药物
Recombinant Human Plasminogen Activator
Recombinant Human Plasminogen Activator
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Cell line expressing mutated human tissue-type plasminogen activator, the constructing strategy thereof and method of preparing expressed protein
US 7632677 B2
申请人: XIA JIAHUI
优先权: 2000
CN
US
3 件公开
Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars
US 7807457 B2
申请人: TGT LAB S A DE C V
优先权: 2000
US
2 件公开
Pharmaceutical composition comprising at least one thrombolytic agent (A) and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
US 8435569 B2
申请人: ABRAINI JACQUES H
优先权: 2008
US
2 件公开
Recombinant glycoproteins, method for the production thereof, medicaments containing said glycoproteins and use thereof
US 6692931 B1
申请人: REUTTER WERNER
优先权: 1998
US
Technological process of producing recombinant human histiotype plasminogen activator TNK mutant
CN 1468862 A
申请人: GUANGZHOU MINGKANG BIOENGINEER
优先权: 2002
CN
DNA vaccine pVPH for SARS virus
CN 1449827 A
申请人: NO 2 MILITARY MEDICAL UNIV OF
优先权: 2003
CN
Method for Production of a Bioengineered Form of Tissue Plasminogen Activator
US 2009246188 A1
申请人: PATELL VILLOO MORAWALA
优先权: 2005
US
Treatment effect of tissue plasminogen activator kringle-2 on stroke and preparation method for tissue plasminogen activator kringle-2
CN 101886066 A
申请人: NANJING UNIVERSITY OF TECHNOLOGY
优先权: 2009
CN
BLOOD CLOT-DISSOLVING PROTEINS PRODUCED IN SEEDS
CN 107427562 A
申请人: NORTHEASTERN STATE UNIV
优先权: 2015
CN
Fusion protein of genetic recombinant human corticotropin and albumin and expression method
CN 109734816 A
申请人: WANG DAYONG
优先权: 2019
CN
第 1 / 2 页
上一页
下一页
药物
反馈